Search

Introduction: Around 40 percent of women in Spain are unable to achieve orgasm during coital relations, although most can do so through other means. Many of these women do not seek treatment, even though this situation may affect their sexual and relational life. Female Orgasm Disorder (FOD) treatment has seen little innovation since the 1980s. The growing acceptance, technological development, and focus on diversity have contributed to the flourishing of the sex toy industry. This sector has enabled the development of therapeutic devices that have already demonstrated usefulness in addressing other female and male sexual dysfunctions, often making treatments more Accessible. However, more scientific studies are needed on this topic. Objective: Present the results of the utility and safety of using a vibrating device in the management of situational female orgasm disorder (FOD) in a group of women from Spain. Methods: A case report study of an observational, descriptive, prospective nature, involving 19 women undergoing treatment, that meet criteria for lifelong, situational FOD from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) was conducted in Murcia, Spain, from January 2022 to July 2023. Patients were 18 years or older, generally healthy as evidenced by medical history, were sexually active, in a current relationship of 3 months or longer, and participation was voluntary. Patients did not meet criteria for PTSD, psychosis or dissociative disorders, depression or bipolar disorders, were not pregnant or in menopause and did not use drugs known to interfere with sexual functioning. Main outcome measures were assessed using the Female Sexual Function Index (FSFI) domain for orgasm at baseline and after 6 and 12 weeks, as well as the success rate of achieving orgasm during coital relations. Treatment consisted of an educational session where a vibrating device called Crescendo II® and its accompanying resource of different positions, Play Book was provided, along with instructions for using the device during coital relations. Results: Patients had a mean age of 31.19 years (range 27–53). An improvement was observed in the average scores at six and twelve weeks in FSFI orgasmic domain, (mean pre = 1.62 (SD) = 0.42, mean post six weeks = 3.47 (SD) = 1.26, mean post twelve weeks = 3.43 (SD) = 1.25). The success rate (orgasm achievement during intercourse) at the end of the study was 90.47%. Conclusions: This case series suggests that the use of a vibration device could be an effective and safe therapeutic option for female situational anorgasmia in addition to reducing the length and cost of treatment. Future research with experimental designs should confirm the clear potential of the use of these devices in treating FOD and clarify issues related to the most appropriate amplitude and frequency of vibration, as well as the possible long-term effects of using these types of vibration devices in patients. Disclosure: Any of the authors act as a consultant, employee or shareholder of an industry for: Mysteryvibe. [ABSTRACT FROM AUTHOR]

Introduction: Around 40 percent of women in Spain are unable to achieve orgasm during coital relations, although most can do so through other means. Many of these women do not seek treatment, even though this situation may affect their sexual and relational life. Female Orgasm Disorder (FOD) treatment has seen little innovation since the 1980s. The growing acceptance, technological development, and focus on diversity have contributed to the flourishing of the sex toy industry. This sector has enabled the development of therapeutic devices that have already demonstrated usefulness in addressing other female and male sexual dysfunctions, often making treatments more Accessible. However, more scientific studies are needed on this topic. Objective: Present the results of the utility and safety of using a vibrating device in the management of situational female orgasm disorder (FOD) in a group of women from Spain. Methods: A case report study of an observational, descriptive, prospective nature, involving 19 women undergoing treatment, that meet criteria for lifelong, situational FOD from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) was conducted in Murcia, Spain, from January 2022 to July 2023. Patients were 18 years or older, generally healthy as evidenced by medical history, were sexually active, in a current relationship of 3 months or longer, and participation was voluntary. Patients did not meet criteria for PTSD, psychosis or dissociative disorders, depression or bipolar disorders, were not pregnant or in menopause and did not use drugs known to interfere with sexual functioning. Main outcome measures were assessed using the Female Sexual Function Index (FSFI) domain for orgasm at baseline and after 6 and 12 weeks, as well as the success rate of achieving orgasm during coital relations. Treatment consisted of an educational session where a vibrating device called Crescendo II® and its accompanying resource of different positions, Play Book was provided, along with instructions for using the device during coital relations. Results: Patients had a mean age of 31.19 years (range 27–53). An improvement was observed in the average scores at six and twelve weeks in FSFI orgasmic domain, (mean pre = 1.62 (SD) = 0.42, mean post six weeks = 3.47 (SD) = 1.26, mean post twelve weeks = 3.43 (SD) = 1.25). The success rate (orgasm achievement during intercourse) at the end of the study was 90.47%. Conclusions: This case series suggests that the use of a vibration device could be an effective and safe therapeutic option for female situational anorgasmia in addition to reducing the length and cost of treatment. Future research with experimental designs should confirm the clear potential of the use of these devices in treating FOD and clarify issues related to the most appropriate amplitude and frequency of vibration, as well as the possible long-term effects of using these types of vibration devices in patients. Disclosure: Any of the authors act as a consultant, employee or shareholder of an industry for: Mysteryvibe. [ABSTRACT FROM AUTHOR]

Introduction: Erectile dysfunction (ED) is a sexual dysfunction that affects the sexual health of millions of men around the world. In recent years, the evidence indicates an increase in cases of ED among individuals under 40 years old. In most cases, the etiology is of psychogenic origin. Cognitive-behavioral therapy (CBT) has been proven effective and remains one of the most widely used treatments for ED in these cases although controlled studies are lacking. One of the most effective CBT techniques is a set of activities performed by a couple, known as systematic desensitization (SD). SD involves gradually exposing the patient to feared intimacy-related activities with their partner. However, many patients do not have a stable partner or do not want their partner to participate in the treatment. Technological advances are helping to create virtual SD programs which are able to reproduce the sights, sounds, and other sensations of the feared situation. Objective: Our goal is to determine the potential usefulness of a new virtual reality-based SD program for the treatment of psychogenic ED (pED). Methods: Six sexually active men diagnosed with pED based on criteria for Erectile Disorder from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) completed virtual SD over 8 weeks. The program consisted of one educational session and five different virtual reality audio exercises which were completed at home using a masturbation aid device called Myhixel ED01, that is connected to a smartphone. The five-item Spanish version of the International Index of Erectile Function (IIEF-5) questionnaire was used to assess symptoms before and after the treatment and the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire was used for evaluating satisfaction with treatment. Results: Patients enrolled had a mean age of 34.83 years (range 27–39) and experienced an improvement in erectile function, mean IIEF-5 score pretreatment was 11(range 9–13) mean posttreatment IIEF score was 18 (range 14–21). The mean EDITS index score at the end of the treatment was 64.70 (range 59–70.25). No adverse effects were reported during the treatment. Conclusions: This case series suggests that the use of a virtual reality-based SD could be a potentially effective and safe therapeutic option for men with pED. This new treatment would facilitate greater access of men with pED to one of the most commonly used strategies of sexual therapy, as it would no longer require the participation of a partner. Studies with adequate sample sizes, control groups, randomization, and follow-up are needed to determine the effectiveness of this new treatment. Disclosure: Any of the authors act as a consultant, employee or shareholder of an industry for: NEW WELLNESS CONCEPT SL. [ABSTRACT FROM AUTHOR]

Introduction: Erectile dysfunction (ED) is a sexual dysfunction that affects the sexual health of millions of men around the world. In recent years, the evidence indicates an increase in cases of ED among individuals under 40 years old. In most cases, the etiology is of psychogenic origin. Cognitive-behavioral therapy (CBT) has been proven effective and remains one of the most widely used treatments for ED in these cases although controlled studies are lacking. One of the most effective CBT techniques is a set of activities performed by a couple, known as systematic desensitization (SD). SD involves gradually exposing the patient to feared intimacy-related activities with their partner. However, many patients do not have a stable partner or do not want their partner to participate in the treatment. Technological advances are helping to create virtual SD programs which are able to reproduce the sights, sounds, and other sensations of the feared situation. Objective: Our goal is to determine the potential usefulness of a new virtual reality-based SD program for the treatment of psychogenic ED (pED). Methods: Six sexually active men diagnosed with pED based on criteria for Erectile Disorder from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) completed virtual SD over 8 weeks. The program consisted of one educational session and five different virtual reality audio exercises which were completed at home using a masturbation aid device called Myhixel ED01, that is connected to a smartphone. The five-item Spanish version of the International Index of Erectile Function (IIEF-5) questionnaire was used to assess symptoms before and after the treatment and the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire was used for evaluating satisfaction with treatment. Results: Patients enrolled had a mean age of 34.83 years (range 27–39) and experienced an improvement in erectile function, mean IIEF-5 score pretreatment was 11(range 9–13) mean posttreatment IIEF score was 18 (range 14–21). The mean EDITS index score at the end of the treatment was 64.70 (range 59–70.25). No adverse effects were reported during the treatment. Conclusions: This case series suggests that the use of a virtual reality-based SD could be a potentially effective and safe therapeutic option for men with pED. This new treatment would facilitate greater access of men with pED to one of the most commonly used strategies of sexual therapy, as it would no longer require the participation of a partner. Studies with adequate sample sizes, control groups, randomization, and follow-up are needed to determine the effectiveness of this new treatment. Disclosure: Any of the authors act as a consultant, employee or shareholder of an industry for: NEW WELLNESS CONCEPT SL. [ABSTRACT FROM AUTHOR]

Introduction: The current non-pharmacological treatment of psychogenic erectile dysfunction (pED) is based on cognitive-behavioral interventions that often involve the participation of the partner, such as desensitization procedures, sensory focusing, and couples counseling. However, it is important to note that in many cases, patients may not have a stable partner or their partner cannot participate in the treatment. The application of local mechanical vibration has shown promising results in increasing skin blood flow and nitric oxide production in healthy young adults. The relaxation of smooth muscle in the penis initiates and maintains an erection. The local release of nitric oxide from autonomic dilator nerves and vascular endothelium is crucial in initiating and sustaining this process. Technological advances have allowed the design of vibrating devices that men can use during sexual encounters. Objective: To determine if the on-demand use of a focused vibration device can increase blood flow and promote relaxation of erectile tissue to improve erectile function in patients with pED. Methods: Seven sexually active men diagnosed with pED based on criteria for Erectile Disorder from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and without a stable partner, were instructed to use a vibrating device called TENUTO II during their sexual encounters for duration of 8 weeks. This device generates focal vibrations on the penis and the perineal area in intervals of 10 seconds of vibration followed by 10 seconds of pause, with a frequency of 50Hz and an amplitude of 2mm. The five-item Spanish version of the International Index of Erectile Function (IIEF-5) questionnaire was used to assess symptoms before and after the procedure and the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire was used for evaluating satisfaction with treatment. Results: After the using the device, all patients enrolled with a mean age of 36.1 years (range 28-45) experienced an improvement in erectile function, mean IIEF-5 score pretreatment was 11(range 5–13) mean posttreatment IIEF score was 20 (range 18-27). No adverse effects were reported during the treatment. Conclusions: This case series suggests that use of an on-demand focused vibration device could be a potentially effective and safe therapeutic option for men with pED. However, further studies with a larger number of participants and a more rigorous research design are needed to confirm these preliminary findings. Disclosure: Yes, this is sponsored by industry/sponsor: MysteryVibe. Clarification: Industry funding only - investigator initiated and executed study. Any of the authors act as a consultant, employee or shareholder of an industry for: Mysteryvibe. [ABSTRACT FROM AUTHOR]